Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.

Biochemical pharmacology - 1 Apr 2002

Ma Jianguo, Murphy Maureen, O'Dwyer Peter J, Berman Eric, Reed Karin, Gallo James M

Abstract excerpt

Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas. To investigate resistance mechanisms in a multidrug therapeutic approach, a TMZ-resistant human glioma cell line, SF188/TR, was established by stepwise exposure of human SF188 parental cells to TMZ for approximately 6 months. SF188/TR showed 6-fold resistance to TMZ and cross-resistance to a broad spectrum of other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Drug Screening Assays, Antitumor

Share to Mismatch Repair Endonuclease PMS2

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Paclitaxel

Share to Temozolomide

Source

Identifiers

PMID: 11960598
DOI: 10.1016/s0006-2952(02)00876-6

Genes

AGT
GEM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.PMID 11960598Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

Overview of tumor cell chemoresistance mechanisms.Semantic proximity Read ↗

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cellsSemantic proximity Read ↗

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.Semantic proximity Read ↗

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational ApplicationsSemantic proximity Read ↗

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivoSemantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signalSemantic proximity Read ↗

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant GlioblastomaSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

General Mechanisms of Resistance to Pharmacological Therapy Applied to Tumor CellsSemantic proximity Read ↗

Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.